Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

September 18, 2026

Study Completion Date

October 28, 2026

Conditions

SCLC

Interventions

DRUG

Topotecan - usual

Topotecan Capsule

DRUG

Topotecan - study

China Import Topotecan Capsule

Trial Locations (1)

Medicine Invention Design Incorporation, Rockville

All Listed Sponsors

collaborator

UnitedHealthcare

OTHER

lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY